What is Syndax's mission?

Syndax's mission is to advance the next generation of targeted treatments to realize a future in which people with cancer live longer and better than ever before. The company is committed to scientific excellence and serving the patient community by delivering therapeutics that provide meaningful and differentiated clinical results and address urgent unmet needs.

What are the key highlights of Syndax's pipeline?

Syndax's innovative pipeline includes two late-stage candidates, revumenib and axatilimab, with the potential to be approved in the U.S. in

Voyager DB

Deep data on millions of local businesses, with verified decision-makers to reveal.

Contact Research

Hand-built prospect lists from human researchers, delivered in 24 hours.

People Search

Find owners and decision-makers by job title, seniority and department.

Chrome Extension

Coldlytics in your browser - prospect any business as you browse the web.

Integrations

Instantly, Smartlead, lemlist, Clay, HighLevel, plus Claude and ChatGPT over MCP.

Voyager DBDeep data on millions of local businesses, with verified decision-makers to reveal.Contact ResearchHand-built prospect lists from human researchers, delivered in 24 hours.People SearchFind owners and decision-makers by job title, seniority and department.Chrome ExtensionColdlytics in your browser - prospect any business as you browse the web.IntegrationsInstantly, Smartlead, lemlist, Clay, HighLevel, plus Claude and ChatGPT over MCP.

PricingPricing AgenciesAgencies BlogBlog

LoginLogin

Syndax

$30.0M revenue • 200 employees • 730 3rd Ave #900, New York, NY, 10017, United States

Last Updated Feb 18, 2026

Own this business? Claim & update this listing →

Company Overview

Company Name

Syndax

Address

730 3rd Ave #900, New York, NY, 10017, United States

Website

syndax.com

Phone

(781) 419-1400

Approx. Annual Revenue

$30.0M

Employees

200

Established

2004

About Syndax

Syndax is a clinical-stage oncology company based in Waltham, Massachusetts, with approximately 51 employees. The company is focused on developing targeted treatments for acute leukemias and chronic graft-versus-host disease, with two late-stage drug candidates, revumenib and axatilimab, that have the potential to be approved in the U.S. by 2024.

Business Profile

Read from the Syndax website on Oct 27, 2026. Hover an item to see the exact wording it came from.

About the website

Website quality (AI-assessed): 8/10 · Current press releases and news; Clear pipeline and product information
Footer copyright year: 2026

Recent changes

What changed on the Syndax website and Google listing, as detected by Coldlytics on each visit.

Oct 27, 2026
Estimated revenue band moved from $5M-10M to $25M-100M
Oct 27, 2026
Estimated headcount moved from 21-50 to 101-250 employees
Oct 27, 2026
Google Ads pixel installed

Coldlytics tracks changes like these across millions of businesses, so you can reach companies the moment they add a pixel, start hiring, or switch software.

Find companies by what just changed →

Biotech & Life Sciences Companies near New York, NY

Browse all Biotech & Life Sciences companies in New York →

Frequently Asked Questions about Syndax

Advertising Pixels

Google Ad Pixel

Technologies Used

Social Profiles

Key Decision Makers

Sophia C. Clinical Trial Specialist

Caroline Larisa Clinical Trial Associate

Shaun Ricketts Clinical Trial Manager, Expanded Access Program and Compassionate Use

Mandy Plemons Clinical Trial Manager, Study Start Up

Christina K. Clinical Trial Manager

Susan Brouwer Senior Clinical Trial Manager